Boston gets CE-mark for second DES (drug-eluting stent)
This article was originally published in Clinica
Executive Summary
Boston Scientific has received European approval for a second drug-eluting stent (DES), Promus, which elutes the immunosuppressant drug everolimus for preventing stent restenosis.